Тактика лечения пациентов с распространенным раком легкого с выявленной мутацией гена EGFR

  • Авторы: Болотина ЛВ1
  • Учреждения:
    1. Московский научно-исследовательский онкологический институт им. П.А.Герцена - филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России
  • Выпуск: Том 19, № 2 (2017)
  • Страницы: 5-9
  • Раздел: Статьи
  • URL: https://journals.rcsi.science/1815-1434/article/view/27126
  • ID: 27126

Цитировать

Полный текст

Аннотация

В статье представлены современные взгляды на лечение распространенных форм немелкоклеточного рака легкого с наличием активирующих мутаций в генах EGRF. Рассмотрены возможности эффективного использования таргетных препаратов для этих клинических ситуаций. Изложены представления о механизмах развития резистентности к таргетной терапии и предложены возможные варианты терапии в таких случаях.

Об авторах

Л В Болотина

Московский научно-исследовательский онкологический институт им. П.А.Герцена - филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России

Email: lbolotina@yandex.ru
д-р мед. наук, рук. отд-ния химиотерапии МНИОИ им. П.А.Герцена - филиала ФГБУ НМИРЦ 125284, Россия, Москва, 2-й Боткинский пр., д. 3

Список литературы

  1. Каприн А.Д., Старинский В.В. и др. Состояние онкологической помощи населению России в 2014 году. М., 2015.
  2. Chemotherapy in non - small cell lung cancer: a meta - analysis using updated data on individual patients from 52 randomised clinical trials. Non - small cell Lung Cancer Collaborative Group. BMJ 1995; 311: 889-909.
  3. Ciuleanu T et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non - small - cell lung cancer: a randomised, double - blind, phase 3 study. Lancet 2009; 374: 1432-40.
  4. Schiller J.H et al. Comparison of four chemotherapy regimens for advanced non - small - cell lung cancer. N. Engl J Med 2002; 346: 92-8.
  5. Sandler A et al. Paclitaxel - carboplatin alone or with bevacizumab for non - small - cell lung cancer. N Engl J Med 2006; 355: 2542-50.
  6. Scagliotti G et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14: 253-63.
  7. Fukuoka M et al. Biomarker analyses and final overall survival results from a phase III, randomized, open - label, first - line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small - cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-74.
  8. Reck M et al. Management of non - small - cell lung cancer: recent developments. Lancet 2013; 382: 709-19.
  9. Cheng L et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012; 25: 347-69.
  10. Harris T.J, Mc Cormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7: 251-65.
  11. Seshacharyulu P et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 15-31.
  12. Yarden Y et al. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
  13. Baselga J et al. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am 2002; 16: 1041-63.
  14. Herbst R.S et al. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Invest Drugs 2002; 11: 837-49.
  15. Arteaga C.L. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell 2006; 9: 421-3.
  16. Gazdar A.F et al. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 2004; 10: 481-6.
  17. Hendricks B.S et al. Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. Systems Biology 2006; 153: 457-66.
  18. Sordella R et al. Gefitinib - sensitizing EGFR mutations in lung cancer activate anti - apoptotic pathways. Science 2004; 305: 1163-7.
  19. Tjulandin S et al. Prospective cohort study of clinical characteristics and management patterns for patients with non - small - cell lung cancer in the Russian Federation: EPICLIN-Lung. Curr Med Res Opin 2015; 31 (6): 1117-27.
  20. Sharma S.V et al. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer 2007; 7: 169-81.
  21. Rosell R et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361 (10): 958-67.
  22. Mok T.S et al. Gefitinib or carboplatin - paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
  23. Моисеенко В.М., Проценко С.А., Семенов И.И. Применение Ирессы (гефитиниба) в качестве терапии первой линии для лечения неоперабельных аденокарцином легкого, содержащих мутацию в гене EGFR // Современная онкология. 2010; 12 (1): 60-6.
  24. Stewart E.L et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations - a review. Transl Lung Cancer Res 2015; 4 (1): 67-81.
  25. Практические рекомендации по лечению злокачественных опухолей. URL: http://www.rosoncoweb.ru/standarts/RUSSCO/ 01.pdf
  26. NCCN Guidelines. URL: http://www.nccn.org/ professionals/ physician gls/pdf/nscl.pdf
  27. Reck M et al. Metastatic non - small - cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol 2014; 25 (Suppl. 3): iii27-39.
  28. Leighl N.B et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 2014; 32 (32): 3673-9.
  29. Горбунова В.А., Артамонова Е.В., Бредер В.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли. 2016; 4. (Спецвып. 2): 22-33.
  30. Johnson B.E et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2013; 31 (Suppl.): abstr. 8019.
  31. Maemondo M et al. Gefitinib or chemotherapy for non - small - cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
  32. Mitsudomi T et al. Gefitinib versus cisplatin plus docetaxel in patients with non - small - cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
  33. Lin J.J et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol 2016; 11 (4): 556-65.
  34. Scagliotti G.V et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy - naive patients with advanced - stage non - small - cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
  35. Zhang L et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non - small - cell lung cancer (INFORM; C-TONG 0804): a multicentre, double - blind randomised phase 3 trial. Lancet Oncol 2012; 13 (5): 466-75.
  36. Burotto M et al. Gefitinib and erlotinib in metastatic non - small cell lung cancer: a meta - analysis of toxicity and efficacy of randomized clinical trials. Oncologist 2015; 20: 400-10.
  37. Park K et al. Afatinib versus gefitinib as first - line treatment of patients with EGFR mutation - positive non - small - cell lung cancer (LUX-Lung 7): a phase 2B, open - label, randomised controlled trial. Lancet Oncol 2016; 17: 577-89.
  38. Park K et al. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. JAMA Oncol 2016; 2 (3): 305-12.
  39. Weickhardt A.J et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene - addicted non - small - cell lung cancer. J Thorac Oncol 2012; 7 (12): 1807-14.
  40. Cortot A.B, Jänne P.A. Molecular mechanisms of resistance in epidermal growth factor receptor - mutant lung adenocarcinomas. Eur Respir Rev 2014; 23 (133): 356-66.
  41. Jackman D et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non - small - cell lung cancer. J Clin Oncol 2010; 28 (2): 357-60.
  42. Yu H.A et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-7.
  43. Oxnard G.R et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011; 17 (6): 1616-22.
  44. Sun J.M et al. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 2013; 82: 294-8.
  45. Kuiper J.L et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 2014; 85: 19-24.
  46. Li W et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer 2014; 84: 295-300.
  47. Kobayashi S et al. EGFR mutation and resistance of non - small - cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92.
  48. Cross D.A et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-61.
  49. Yun C.H et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105: 2070-5.
  50. Kris M.G et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311 (19): 1998-2006.
  51. Fukuoka M et al. Multi - institutional randomized phase II trial of gefitinib for previously treated patients with advanced non - small - cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21 (12): 2237-46.
  52. Kris M.G et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non - small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58.
  53. Mok T, Yang J.J, Lam K.C. Treating patients with EGFR-sensitizing mutations: first line or second line -- is there a difference? J Clin Oncol 2013; 31 (8): 1081-8.
  54. Park K. LUX-Lung 7: is there enough data for a final conclusion? Lancet Oncol 2016; 17 (7): e268-9.
  55. Sequist L.V et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31 (27): 3327-34.

© ООО "Консилиум Медикум", 2017

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах